Novo Nordisk hemophilia med OKd

 

• FDA approval is based on data from the pivotal phase 3 trial (explorer7) establishing the safety and efficacy of Alhemo® for daily prevention of bleeds in adults and pediatric patients 12 years of age and older living with hemophilia A or B with inhibitors
• Results from the pivotal trial showed an 86% reduction in treated spontaneous and traumatic bleeds in patients using Alhemo® prophylaxis compared to no prophylaxis1
• This approval marks the first subcutaneous injection treatment of its kind for use in this patient population

https://www.prnewswire.com/news-releases/fda-approves-alhemo-injection-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-with-inhibitors-302337790.html